Life Sciences Market Research News ASDReports, Press Releases

New PoC Mobile Radio MNC360: The Right Choice for In-Vehicle Communication On May 26th, 2022, Hytera announced the launch of MNC360, a PoC mobile radio designed to help transportation users to communicate easily and efficiently while also providing safe driving functions and a wide range of supplementary services. The MNC360 is compact and lightweight. The 39.3mm ultra-thin body and ergonomic design make it easy to install. The snap-in bracket design facilitates the installation and uninstallation. The rotatable rugged bearing allows users to adjust angles easily. P... 13 Jun, 2022
Exothera Develops ExoREADY, a Ready-to-use Viral Vector Production Platform, to Accelerate Advanced Therapy Manufacture ...Exothera S.A., a leading CDMO that specializes in the development and manufacture of viral vectors for vaccines and gene therapies, has developed and is continuing improving the exoREADY platform for accelerated viral vector manufacture. This fully integrated platform will ensure faster, more cost-effective production of viral vector-based therapeutics (for gene therapy, vaccines, and oncolytic viruses for cancer treatment) at scale. Viral vector-based cell and gene therapies are increasingly... 9 Jun, 2022
JBBDCo Introduces Hardin's Creek™, a New Series of Unique and Rare, Limited-edition Whiskeys Rooted in the Beam Family L...Today, the James B. Beam Distilling Company (JBBDCo) celebrates the launch of Hardin's Creek™, a new brand that will chart the ongoing story of the Beam family legacy, one that is more than 227 years in the making, through highly limited and rare releases. Hardin's Creek is the next generation of boundary-pushing, premium American Whiskey inspired by the expertise of seven generations of Beam Master Distillers. Hardin's Creek is an ongoing series of annual releases, featurin... 2 Jun, 2022
OncoHealth™ Unveils Real-World Evidence Dashboard for Pan Tumor, Immunotherapy ResearchOncoHealth, the leading digital health company dedicated to oncology, unveiled, today, a new real-world evidence dashboard that enables researchers to study the comparative effectiveness and market performance of immunotherapies. Powered by clinically rich, real-time, pan tumor immunotherapy data and combined with advanced analytics, DashIO™ provides researchers with the ability to query and visualize low-latency real-world data on immune checkpoint inhibitors. “Immune checkpoint ... 17 May, 2022

Life Sciences News